Teva Pharmaceutical Industries Ltd (ADR) ADR (NYSE:TEVA) is excited because its experimental drug to prevent migraines has made it through the late-stage study. What remains is for the U.S regulatory to approve the drug. In case it gets approved by the body, the company will unveil it in the second half of 2018.That will be great news to a lot of people globally since migraines will no longer be a major threat as it has been over the years.
As a matter of fact, Teva is the Israel’s biggest company. It is also one of the highly rated generic drugmakers worldwide. In a recent analysis by some top analysts, it was outlined that the company had the capacity to generate at least $1 billion in sales annually.
In the past few months, reports indicate that Teva’s stock price plummeted. In giving an explanation, one of the company’s top executives said that it resulted from a series of costly acquisitions and delayed drug launches. He also talked about the wild generic competition that the best-selling multiple sclerosis drug Copaxone was currently facing.
This is not the first company to face such a circumstance. Many more have been here before and thereafter continued with the good performance. The company says that it currently has plans underway that will help it resolve the matter.
According to Reuters.com, the phase III trial in episodic migraine prevention using both monthly and quarterly doses has brought about major revelations regarding the new drug. The researchers behind the trial have said that fremanezumab in a significant way reduced the amount of headaches suffered by the various patients. This is a timely move and will help a lot of suffering persons. It is a serious condition that cannot be assumed since in the past it has claimed many lives.
One week ago, the top provider unveiled positive results for the drug facing out less-prevalent chronic migraines. While speaking to a number of top news reporters, one of the top officials working with the company said, “Teva plans to submit a Biologics License Application to the U.S. Food and Drug Administration for fremanezumab later this year in both episodic and chronic migraine with anticipated approval and launch in the second half of 2018.”
The company looks to doing much more towards raising its position in the world markets.
